In the first study of its kind, the researchers examined 84 people with temporal lobe epilepsy (epilepsy arising from the temporal lobe at the sides of the head) and hippocampal sclerosis (a ...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a rare neurodegenerative condition. This designation for ...